Source:http://linkedlifedata.com/resource/pubmed/id/19807569
| Subject | Predicate | Object | Context |
|---|---|---|---|
| pubmed-article:19807569 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19807569 | lifeskim:mentions | umls-concept:C0010181 | lld:lifeskim |
| pubmed-article:19807569 | lifeskim:mentions | umls-concept:C1512814 | lld:lifeskim |
| pubmed-article:19807569 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:19807569 | pubmed:dateCreated | 2009-10-7 | lld:pubmed |
| pubmed-article:19807569 | pubmed:abstractText | Technical advances have given medicine the opportunity to refine current treatment techniques to improve outcomes. Computed tomography, magnetic resonance imaging and high energy linear accelerators are but a few examples of technology translating into clinical practice. Intensity-modulated radiation therapy is a form of 3D conformal radiation that is being increasingly incorporated into the management of patients with prostate cancer. As with any new technology, the cost of intensity-modulated radiation therapy is considerably greater than standard therapy. Economic models can be useful to compare treatments when this comparison cannot be performed in a clinical trial. A Markov Model was used to compare the use of intensity-modulated radiation with 3D conformal radiation therapy in the treatment of a 70 year old man with a good- and intermediate-risk prostate cancer. Cost data for men with Medicare insurance and prostate cancer treated with intensity-modulated radiation therapy and 3D conformal radiation therapy was obtained from the billing department at the Fox Chase Cancer Center (PA, USA). Utilities were collected from men undergoing intensity-modulated radiation therapy and 3D conformal radiation therapy for prostate cancer. Intensity-modulated radiation therapy was found to be cost effective in the treatment of a 70 year old man with prostate cancer with a incremental cost-effectiveness ratio of USD 16,182/quality-adjusted life year for men with intermediate-risk prostate cancer and USD 17,448/ quality-adjusted life year for men with good-risk prostate cancer. Sensitivity analysis found that a longer time horizon of the analysis and younger age at treatment favorably impact the cost-effectiveness ratio. | lld:pubmed |
| pubmed-article:19807569 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19807569 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19807569 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:19807569 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:19807569 | pubmed:issn | 1744-8379 | lld:pubmed |
| pubmed-article:19807569 | pubmed:author | pubmed-author:KonskiAndreA | lld:pubmed |
| pubmed-article:19807569 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19807569 | pubmed:volume | 5 | lld:pubmed |
| pubmed-article:19807569 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19807569 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19807569 | pubmed:pagination | 137-40 | lld:pubmed |
| pubmed-article:19807569 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:19807569 | pubmed:articleTitle | Cost-effectiveness of intensity-modulated radiation therapy. | lld:pubmed |
| pubmed-article:19807569 | pubmed:affiliation | Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111, USA. andre.konski@fccc.edu | lld:pubmed |
| pubmed-article:19807569 | pubmed:publicationType | Journal Article | lld:pubmed |